Dr Mark Kris examines new OS results for chemo plus osimertinib in EGFR-mutant NSCLC and how they align with survival gains seen previously with other EGFR TKIs.

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all ...

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

NSCLC remains the leading cause of cancer-related mortality worldwide, with EGFR mutations being a critical driver in approximately 10-15% of lung adenocarcinomas in Western populations, and up to 40% ...

Accelerated repopulation is a main reason for locoregional failure after fractionated radiotherapy for head and neck squamous cell carcinoma (HNSCC). Epidermal growth factor receptor (EGFR) is a key ...

“We postulate that these observations may provide novel opportunities for therapeutic interventions for EGFR driven cancers.” “We postulate that BUB1 helps in the formation and stabilization of EGFR ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved a new, simplified monthly dosing schedule for Johnson & Johnson’s JNJ Rybrevant Faspro (amivantamab and hyaluronidase-lpuj). When ...